Skip to main content
. Author manuscript; available in PMC: 2016 May 24.
Published in final edited form as: J Bone Miner Res. 2014 Jan;29(1):260–267. doi: 10.1002/jbmr.2023

Table 3.

Class of Anti-Osteoporosis Medication Received

≥2 fractures while on AOM
(n = 73)
1 fracture while on AOM
(n = 359)
No fractures while on AOM
(n = 5118)
Bisphosphonate (oral) 64 (88) 312 (87) 4213 (82)
Bisphosphonate (injection or infusion) 3 (4.1) 5 (1.4) 56 (1.1)
Parathyroid hormone 0 1 (0.3) 4 (0.1)
SERM 4 (5.5) 34 (9.5) 602 (12)
Calcitonin hormone 1 (1.4) 3 (0.8) 48 (0.9)
Strontium ranelate 0 5 (1.4) 80 (1.6)
Steroid hormone 1 (1.4) 2 (0.6) 161 (3.2)
Bisphosphonates + SERM 0 2 (0.6) 41 (0.8)
Bisphosphonates + strontium ranelate 0 1 (0.3) 0
Bisphosphonates + steroid hormone 0 0 1 (0.02)
Bisphosphonates + calcitonin hormone 0 0 3 (0.1)
Calcitonin hormone + strontium ranelate 0 0 1 (0.02)

SERM = selective estrogen receptor modulator.